Human parvovirus B19 infection and anemia.
| Patient . | RBC Lifespan . | Immune Status . | Time Required to Mount an Effective Immune Response . | Outcome . |
|---|---|---|---|---|
| Normal individual | 120 d | Normal | 14-21 d | Normal Hct is maintained |
| Chronic hemolysis | 5-10 d | Normal | 14-21 d | Acute (transient) PRCA |
| HIV | 120 d | Abnormal | Unable to clear B19 | PRCA |
| Erythropoiesis is suppressed in all patients infected with B19. Recovery occurs at 14-21 days (as B19 is cleared) in those individuals with normal immune function. Patients with chronic hemolysis develop a severe (transient) anemia, termed “aplastic crisis,” because their RBC lifespan is short. Patients with HIV may be unable to clear B19 and thus can develop anemia after 2-4 months. | ||||
| Patient . | RBC Lifespan . | Immune Status . | Time Required to Mount an Effective Immune Response . | Outcome . |
|---|---|---|---|---|
| Normal individual | 120 d | Normal | 14-21 d | Normal Hct is maintained |
| Chronic hemolysis | 5-10 d | Normal | 14-21 d | Acute (transient) PRCA |
| HIV | 120 d | Abnormal | Unable to clear B19 | PRCA |
| Erythropoiesis is suppressed in all patients infected with B19. Recovery occurs at 14-21 days (as B19 is cleared) in those individuals with normal immune function. Patients with chronic hemolysis develop a severe (transient) anemia, termed “aplastic crisis,” because their RBC lifespan is short. Patients with HIV may be unable to clear B19 and thus can develop anemia after 2-4 months. | ||||